Loading ......
Carlumab is a human antibody against CCL2, the monocyte chemoattractant that recruits tumour-associated macrophages and sustains the inflammatory microenvironment of several solid tumours. Conjugating this antibody to a maytansinoid payload through an SPDB linker creates a molecule that delivers cytotoxic drug to chemokine-rich tissue while simultaneously interrupting a signalling axis that supports tumour progression. The dual mechanism makes exposure assessment unusually informative, because the antibody component has pharmacological activity independent of payload delivery, and because the same antibody has been paired with different linker–payload systems during development. Analysing these variants side by side clarifies how conjugation chemistry influences circulatory stability, target engagement and the balance between chemokine neutralisation and cytotoxic delivery.
Figure 1. Anti-CCL2 (Carlumab)-SPDB-DM4 ADC Immunoassay for Chemokine-Targeted Payload Exposure.
The SPDB linker connects the antibody to DM4 through a disulfide bond that is reduced preferentially in the intracellular environment, releasing a membrane-permeable maytansinoid metabolite capable of diffusing to neighbouring cells. This bystander effect extends activity beyond the antigen-positive population but also introduces a route by which payload reaches normal tissue. Because the conjugate circulates as a mixture of species with different payload loads, an assay directed at the intact molecule reports a population average rather than a single defined entity. Interpretation therefore depends on knowing whether the reagents recognise the payload, the linker or the antibody alone. For carlumab conjugates, where several linker–payload combinations exist, the ability to measure each variant with matched reagents allows direct comparison of stability and exposure, and it supports the mechanistic question of whether chemokine neutralisation or payload delivery drives the observed antitumour effect. Such comparisons are only meaningful when the assays used have been characterised for cross-reactivity against the other variants in the series.
| Carlumab Conjugate Species and Ligand Parameters | Details |
| C-C Motif Chemokine Ligand (CCL2) | CCL2 signals through CCR2 to recruit monocytes and to polarise macrophages toward a tumour-promoting phenotype. Its concentration rises in several malignancies and correlates with poor prognosis, making both the ligand and its receptor attractive targets for therapeutic intervention. |
| Intact Carlumab-SPDB-DM4 Conjugate | The intact species carries antibody, reducible linker and maytansinoid payload, and it is the form capable of target-directed delivery. Its measurement requires reagents that discriminate the conjugated antibody from unconjugated carrier and from conjugates bearing other linker chemistries. |
| Free CCL2 after Treatment | Residual ligand during therapy indicates incomplete neutralisation and continued monocyte recruitment. Measuring free chemokine alongside conjugate exposure separates the pharmacodynamic effect of the antibody from the cytotoxic effect of the payload. |
| Linker–Payload Variants | The same antibody has been conjugated through non-cleavable and alternative cleavable linkers carrying different maytansinoids. Comparing these variants with matched assays reveals how linker chemistry alters circulatory half-life, payload retention and bystander activity. |
A conjugate that neutralises its own target creates an analytical complication that ordinary antibody assays ignore: as the antibody binds CCL2, it is removed from the free pool while remaining detectable as total drug. In tumours with high chemokine production, this sequestration can consume a substantial fraction of the administered dose before any payload reaches a cell. Measuring free CCL2 and intact conjugate together therefore describes a competition that neither measurement captures alone. When free ligand remains high despite adequate conjugate exposure, the implication is that production outpaces neutralisation and that dose escalation may add little. When free ligand falls while conjugate concentration declines steeply, the pattern suggests target-mediated clearance is dominating the pharmacokinetic profile. These interpretations matter for dose selection because they point toward different interventions: increasing dose, shortening the interval, or accepting that the chemokine axis is saturated and that further benefit must come from payload delivery. Laboratories supporting chemokine-directed conjugates benefit from establishing both measurements before clinical testing begins, since retrospective addition of a ligand assay to a completed study rarely recovers the analytical quality that prospective design provides.
| Products | Core Advantages | Primary Applicable Scenarios |
| Anti-CCL2 (Carlumab)-SPDB-DM4 (ADC) ELISA Kit | A conjugate-specific assay recognising the SPDB-linked maytansinoid form of carlumab, with reagents selected to avoid cross-reactivity against unconjugated antibody and against alternative linker variants. The format performs in human and preclinical serum and plasma and supports the dilution ranges required for pharmacokinetic sampling. | Conjugate exposure monitoring, linker stability assessment, and comparison of SPDB-DM4 behaviour with other payload systems. |
| Anti-CCL2 (Carlumab)-McMMAF (ADC) ELISA Kit | Measures the non-cleavable auristatin conjugate of the same antibody, enabling direct comparison between linker chemistries within a single programme. The assay uses matched reagents that preserve specificity for the McMMAF form and delivers reproducible quantitation across matrices. | Linker chemistry comparison, payload release profiling, and candidate selection within a conjugate series. |
| Anti-CCL2 (Carlumab)-SMCC-DM1 (ADC) ELISA Kit | A third variant-specific assay directed at the SMCC-linked maytansinoid conjugate, completing a series that allows several conjugation strategies to be evaluated with equivalent methodology. Consistent format and interpretation logic across the series reduces the risk of artefactual differences between arms. | Conjugation strategy evaluation, cross-variant specificity studies, and stability comparison across linker classes. |
| Human CCL2/MCP-1 ELISA Kit | Quantifies the free chemokine in serum, plasma and culture supernatant with a matched antibody pair and calibrated standards. The assay detects CCL2 across the range observed in inflammatory and malignant states, providing the ligand-side context required to interpret conjugate exposure. | Target engagement assessment, disease activity correlation, and mechanistic studies of chemokine neutralisation. |
The variant series was designed for comparison, and its greatest value emerges when several conjugation strategies are evaluated under equivalent analytical conditions.
Chemokine-directed conjugates ask the analyst to measure distinct pharmacological stories at once, and the carlumab series makes that demand explicit by pairing a neutralising antibody with several distinct payload systems. Variant-specific assays that share methodology allow linker chemistry to be evaluated without confounding analytical differences, while free chemokine measurement places conjugate exposure in the context of target engagement. The Anti-CCL2 (Carlumab)-SPDB-DM4 ELISA Kit, its McMMAF and SMCC-DM1 counterparts, and the Human CCL2/MCP-1 ELISA Kit together provide that complete view. For research groups comparing conjugation strategies and for laboratories supporting chemokine-targeted programmes, this set offers reproducible, cross-characterised reagents that make comparison meaningful.
Loading ......